Clinical trials: Epstein-Barr Virus Infection
Epstein-Barr Virus Infections, Cytomegalovirus Infections
R-MVST Cells for Treatment of Viral Infections
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV)…
- Conditions
- Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Trial name
- NCT05183490
- Testing
- Rapidly generated virus specific T (R-MVST) cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Columbia University
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV or EBV in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
- Trial name
- NCT04364178
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jessie L. Alexander, MD
T-cell Lymphoma, NK-Cell Lymphoma
A Registry for People With T-cell Lymphoma
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma.
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia
- Trial name
- NCT05978141
- Testing
- Optional Blood Sample and Nail Sample
- Where
- 26 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epstein-Barr Virus Infection
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in…
- Trial name
- NCT05164094
- Testing
- mRNA-1189
- Where
- 65 sites in United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Epstein-Barr Virus Infection, Infectious Mononucleosis
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
Background: Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Mono can cause fatigue that lasts more than 6 months, and some people can have severe complications.
- Conditions
- Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
- Trial name
- NCT05683834
- Testing
- Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
EBV Infection After Allogenic HSCT
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.
- Trial name
- NCT06119256
- Testing
- EBV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chinese PLA General Hospital
Epstein-Barr Virus
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.
- Trial name
- NCT07478952
- Testing
- mRNA-1189
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT06256484
- Testing
- ATA3219
- Where
- 6 sites in United States, Australia
- Volunteers
- 1 people
- Sponsor
- Atara Biotherapeutics
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Epstein-Barr Virus-associated Lymphoproliferative Diseases, Chronic Active Epstein-Barr Virus Infection
Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
This clinical trial is designed as a single-arm, two-center, open-label, prospective study. All participants are enrolled in the standard-dose unrelated umbilical cord blood transplantation group to evaluate the efficacy and…
- Conditions
- Epstein-Barr Virus-associated Lymphoproliferative Diseases, Chronic Active Epstein-Barr Virus Infection, EBV Associated Lymphoma, Umbilical Cord Blood Transplant
- Trial name
- NCT07381738
- Testing
- Umbilical cord blood transplantation as treatment of Epstein-Barr virus-associated lymphoproliferative diseases
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Epstein-Barr virus (EBV) DNAemia is a common and potentially serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and may progress to EBV-associated lymphoproliferative disorders.
- Trial name
- NCT07368634
- Testing
- EBV-TCR-T Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Daihong Liu
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
HSCT, EBV Infection
Zuberitamab for EBV Infection Post-Allo-HSCT
EBV DNAemia is defined as the presence of EBV-DNA load in peripheral blood exceeding the normal threshold, serving as a key diagnostic indicator for EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD).
- Trial name
- NCT07261215
- Testing
- Zuberitamab
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Radiologically Isolated Syndrome, Epstein-Barr Virus Infections
Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS Patients
This is an ancillary study using samples collected in the ProBioRIS cohort (NCT06395662). The aim of the project is to highlight new biomarker candidates to assess the risk of conversion to clinically definite multiple sclerosis…
- Trial name
- RIS - EBVD (NCT07256431)
- Testing
- Antibiody titration
- Where
- France
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
EBV Infection, EBV Viremia
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Transplant recipients are treated with immunosuppressive drugs to avoid rejection of the transplanted organ. As the medication impairs the immune response, it also increases the risk of serious infections and cancer in transplant…
- Conditions
- EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
- Trial name
- EVITA (NCT04189835)
- Testing
- EBV DNA in whole blood and plasma
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 509 people
- Sponsor
- University of Aarhus
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
Currently, treatment options for Epstein-Barr virus (EBV) infection are limited, with unsatisfactory efficacy and no established standard therapy.
- Conditions
- Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133776
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Nasopharyngeal Carcinoma
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus (EBV)-associated carcinoma of epidermoid origin. It occurs most commonly in Southern China and Southeast Asia.
- Trial name
- NCT02363400
- Testing
- MEP
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- National Health Research Institutes, Taiwan
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- NCT06909110
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jessie L. Alexander